Estetrol (E4) is a native fetal estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC)

Jonathan Douxfils,Rogerio Lobo,Mélanie Taziaux,Maud Jost,Céline Bouvy,Ulysse Gaspard,Jean-Michel Foidart

doi:10.1016/j.maturitas.2021.08.013

Estetrol (E4) is a native fetal estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC)

Jonathan Douxfils, Rogerio Lobo + Show 5 more

https://doi.org/10.1016/j.maturitas.2021.08.013

Copy DOI

Journal: Maturitas	Publication Date: Oct 1, 2021
Citations: 3

Affiliation: University of Namur, Columbia University Irving Medical Center, Mithra Pharmaceuticals (Belgium), OneBlood, University of Liège

#Normalized Activated Protein C Sensitivity Ratio #Markers In Postmenopausal Women + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Objective: Compared to non-users, the risk of venous thromboembolism (VTE) has been reported to be increased in women using hormonal replacement therapy (HRT). This risk increase is explained, at least in part, by an acquired resistance towards activated protein C (APCr) which is induced by the estrogenic component. The APCr is assessed by measuring the amount of thrombin generated in the absence and presence of exogenous APC. Results are reported as normalized APC sensitivity ratio (nAPCsr), a scale which has been found to correlate with the VTE risk observed in COC and HRT users.

Full Text